Biotech | April 29, 2022
Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Revolution Aspire CT System is manufactured at the company’s new plant launched under the government’s Production Linked Incentives (PLI) Scheme
Recognition illustrates Takeda’s patient-centricity throughout its manufacturing and supply processes
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
It enables precise visualization and treatment access to the left heart
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
The approval by the DCGI comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO)
The approval comes soon after Corbevax was given the nod for 12-15-year group
Covaxin was earlier approved for children 12-18 years of age
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Subscribe To Our Newsletter & Stay Updated
